|Bid||133.76 x 100|
|Ask||137.56 x 100|
|Day's Range||132.76 - 137.26|
|52 Week Range||71.46 - 137.26|
|PE Ratio (TTM)||189.02|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene, Regeneron and Vertex could lead the biotech sector to 15% more upside following the second quarter, an analyst said Thursday.
In 2016, Vertex Pharmaceuticals’ (VRTX) Kalydeco reported revenues of around $703 million, which represents ~11% growth on a YoY (year-over-year) basis.
In 2016, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $979 million, reflecting ~180% YoY (year-over-year) growth.